PRECISION_MRD: Efficacy of Biomarker Directed Systemic Therapy

STUDY TITLE: PRECISION_MRD: A Study Evaluating the Efficacy of Biomarker Directed Systemic Therapy in Colorectal Cancer Patients with Micrometastatic Disease Identified by a ctDNA Molecular Residual Disease Assay

CtDNA technology has allowed for the detection of patients with microscopic metastatic disease despite resection followed by standard of care adjuvant therapy. NCCN guidelines support the use of biomarker directed targeted therapies in the second line setting for metastatic CRC patients. Although there are reported outcomes for second line FOLFIRI for MRD positive CRC patients, targeted second line therapies based on molecular subtypes have not been evaluated. In this study, we will observe the impact of biomarker directed targeted systemic therapy in CRC patients with ctDNA-defined MRD.